Continuous HRV Monitoring for Predicting Response to Biologic Therapy in IBD

Inclusion Criteria: * Diagnosed with UC according to the Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023 · Xi'an) or diagnosed with CD according to the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023 · Guangzhou) at least 3 months before enrollment; * Initiation of IFX or VDZ treatment for the first time based on actual clinical needs; * Concomitant use of stable doses of 5-ASA or immunosuppressants is permitted; * Able and willing to wear an HRV monitoring device and sign an informed consent form. Exclusion Criteria: * Patients receiving combination therapy with two or more biological agents; * History of IBD-related surgery within the past 4 weeks or planned surgery during the study period; * Current severe intestinal infection (e.g., uncontrolled Clostridium difficile or cytomegalovirus infection); * Diagnosed extensive small bowel resection or short bowel syndrome; * Uncontrolled psychiatric disorders (e.g., severe anxiety or depression) or use of anti-anxiety/depressant medications that may affect autonomic nervous function; * Use of medications affecting heart rate or autonomic nervous function without the ability to maintain a stable dose during the trial (e.g., beta-blockers, calcium channel blockers, etc.); * Coexisting conditions related to autonomic dysfunction (e.g., hyperthyroidism, thyroiditis, hypertension, various types of conduction blocks, arrhythmias, etc.).